Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals develops clinical-stage therapies for addiction and related disorders, with its lead investigational product candidate, AD04, focused on alcohol use disorder in heavy drinking patients. News about ADIL commonly centers on AD04 clinical-development planning, FDA-related regulatory discussions, precision-medicine positioning, intellectual property filings, manufacturing and technical-transfer work, and potential commercial pathways for the program.
Company updates also cover financial results, cash runway commentary, Nasdaq listing compliance, and governance or capital-structure actions tied to its public-company status. The recurring business context is a single-segment biopharmaceutical developer advancing a genetically targeted serotonin-3 receptor antagonist approach for alcohol use disorder.
Adial Pharmaceuticals (NASDAQ: ADIL) entered an exclusive collaboration framework with Molteni Farmaceutici on March 3, 2026, to pursue European commercialization of AD04. The framework anticipates nearly $60 million in potential milestones and royalties, subject to a definitive agreement and AD04 progressing through clinical development.
The pact grants Molteni exclusivity to evaluate feasibility and sets terms for upfront, milestone, and tiered royalties (high single to low double digits). Adial cites genotype-driven Phase 3 design, manufacturing arrangements, a patent filing extending LOE to 2045 if granted, and simplified cheek-swab genetic screening.
Adial Pharmaceuticals (NASDAQ: ADIL) regained compliance with Nasdaq Listing Rule 5550(a)(2) after the company's common stock traded with a closing bid of at least $1.00 for 10 consecutive business days from Feb 6–20, 2026. Nasdaq notified the company on Feb 23, 2026 that the matter is closed.
The company said it is advancing AD04 toward a pivotal Phase 3 program, described improvements in clinical strategy, regulatory alignment, and manufacturing readiness, and disclosed ongoing advanced strategic partnering discussions to support next‑phase development and commercialization.
Adial Pharmaceuticals (NASDAQ: ADIL) highlighted recent FDA policy direction that may permit drug approval based on one adequate and well-controlled clinical investigation plus confirmatory evidence rather than two independent pivotal trials, where scientifically justified. This could lower Phase 3 costs, improve capital efficiency, and accelerate an NDA pathway for AD04.
The company plans to engage with the FDA on an appropriate evidentiary strategy for AD04, a genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder.
Adial Pharmaceuticals (NASDAQ: ADIL) announced CEO Cary Claiborne will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026 at 2:40 p.m. ET. The presentation will be webcast live and available for replay.
Adial management will also hold one‑on‑one meetings with approved investors during the virtual conference, held February 25–26, 2026.
Adial (NASDAQ: ADIL) applauded the Feb. 4, 2026 federal appropriations bill that includes a Congressional directive titled “Alternative Clinical Trial Endpoints for Substance Use Disorders.” The law directs the FDA and NIDA to collaborate on non‑abstinence endpoints—such as reduced cravings or disorder severity—that demonstrate meaningful clinical benefit.
Adial says the directive aligns with NIAAA’s updated recovery definition and could strengthen the regulatory pathway for its lead investigational therapy, AD04, which targets Alcohol Use Disorder using a precision medicine approach.
Adial Pharmaceuticals (NASDAQ: ADIL) will effect a 1-for-25 reverse stock split effective Feb 5, 2026 at 11:59 p.m. ET, reducing outstanding common shares from ~27.8 million to ~1.1 million and retaining the ADIL ticker. Common stock will trade on a split-adjusted basis on Feb 6, 2026.
The split is intended to restore compliance with Nasdaq's $1.00 minimum bid price, provide a new CUSIP 00688A304, adjust outstanding equity awards and warrants proportionally, and cash out fractional shares based on the 10-day average closing price preceding effectiveness.
Adial (NASDAQ: ADIL) announced publication of an international PCT patent application for AD04 on January 14, 2026. AD04 is described as the company’s lead investigational genetically targeted serotonin-3 receptor antagonist for treating Alcohol Use Disorder (AUD) in heavy drinking patients (defined in the release as < 10 drinks/drinking day). The company said the patent, if granted, is expected to protect Adial’s core assets through at least 2045. Management attributed the application to an extensive examination of clinical data after hiring new patent counsel and said the filing was originally made in July 2024.
Adial Pharmaceuticals (NASDAQ: ADIL) announced a warrant inducement agreement with an existing healthcare institutional investor to support immediate exercise of existing Series C-1 and Series E warrants at a reduced exercise price of $0.31. The exercises could purchase up to 9,215,675 shares of common stock and generate approximately $2.86 million in gross proceeds before fees and expenses.
In a private placement, the investor will receive new unregistered Series F warrants to purchase up to 13,823,512 shares at $0.31, exercisable after shareholder approval and expiring 24 months after the Approval Date. Closing is expected on or about December 1, 2025, subject to customary conditions.
Adial Pharmaceuticals (NASDAQ: ADIL) reported Q3 2025 results and a business update on Nov 14, 2025. Key regulatory progress included a successful End of Phase 2 (EOP2) meeting with FDA providing guidance on an adaptive Phase 3 design, and confirmation that the company's cheek swab Genomind test is a Non-Significant Risk (NSR) for use in Phase 3. The company targets biomarker-positive (AG+) AUD patients, citing an AG+ prevalence of ~14%. Intellectual property work includes a provisional patent update filed July 9, 2025, expected to protect core assets through 2045. Financially, cash was $4.6M at Sept 30, 2025 (down from $5.9M), the company expects funding into Q2 2026, R&D expense fell ~50% YoY, and net loss was $1.8M for Q3 2025.
Adial Pharmaceuticals (NASDAQ: ADIL) announced that CEO Cary Claiborne was a featured guest on The Big Biz Show. The episode aired on October 15, 2025 on cable networks including Fox Business, NBCUniversal and Time Warner Cable, on streaming services such as Roku, Apple TV and fire TV, and on radio via The Biz Talk Radio Network, Armed Forces Radio and iHeart Media reaching 175 countries.
The program is also available on the company website at www.adial.com/newsroom.